{"protocolSection":{"identificationModule":{"nctId":"NCT00102284","orgStudyIdInfo":{"id":"KS-NEUROMOD_01, Stage Ia"},"secondaryIdInfos":[{"id":"IZKF Muenster: Kne3/074/04"}],"organization":{"fullName":"University Hospital Muenster","class":"OTHER"},"briefTitle":"Neuromodulation and Language Acquisition (Project Stage Ia)","officialTitle":"Improved Language Acquisition Through Neuromodulation, Project Stage Ia"},"statusModule":{"statusVerifiedDate":"2006-09","overallStatus":"TERMINATED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2004-03"},"completionDateStruct":{"date":"2005-04"},"studyFirstSubmitDate":"2005-01-26","studyFirstSubmitQcDate":"2005-01-26","studyFirstPostDateStruct":{"date":"2005-01-27","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-01-26","lastUpdatePostDateStruct":{"date":"2010-01-27","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital Muenster","class":"OTHER"}},"descriptionModule":{"briefSummary":"The purpose of this study is to determine whether levodopa, pergolid, rivastigmine, or modafinil are effective in boosting semantic language acquisition in healthy subjects.","detailedDescription":"Our prior work shows that d-amphetamine and the dopamine precursor levodopa markedly improve word learning success in healthy subjects. In this randomized, placebo-controlled, double-blind clinical trial, we probe whether a mixed d1/d2 dopamine agonist (pergolid) or cholinergic neuromodulation (rivastigmine) or a general centrally arousing substance (modafinil) will yield a learning enhancement comparable to using levodopa in healthy subjects.\n\nOur results show that the dopamine agonist pergolide impaired learning in healthy subjects compared to placebo, whereas cholinergic neuromodulation had no effect."},"conditionsModule":{"conditions":["Healthy"],"keywords":["language acquisition","plasticity","stroke recovery","associative learning"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE"}},"enrollmentInfo":{"count":100}},"armsInterventionsModule":{"interventions":[{"type":"DRUG","name":"levodopa"},{"type":"DRUG","name":"rivastigmine"},{"type":"DRUG","name":"pergolid"},{"type":"DRUG","name":"modafinil"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Boost in language learning success through neuromodulation"}],"secondaryOutcomes":[{"measure":"Stability of language learning success"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy subjects\n* 20-35 years old\n* Right handedness\n* Left language dominance (as assessed by functional transcranial Doppler ultrasonography \\[fTCD\\])\n\nExclusion Criteria:\n\n* Neurological/psychiatric/metabolic/cardiac disorders\n* Asthma\n* Known allergic reactions to one of the experimental drugs\n* Other drugs affecting the central nervous system\n* Leisure drug ingestion during the past 4 weeks (urine test)\n* Smoking cessation during the past 2 weeks\n* \\> 6 cups of coffee or energy drinks per day\n* \\> 10 cigarettes per day\n* \\> 50 grams of alcohol per day","healthyVolunteers":true,"sex":"ALL","minimumAge":"20 Years","maximumAge":"35 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Caterina Breitenstein, PhD","affiliation":"Dept. of Neurology, University Hospital Muenster","role":"STUDY_DIRECTOR"},{"name":"Stefan Knecht, MD","affiliation":"Dept. of Neurology, University Hospital Muenster","role":"STUDY_CHAIR"}],"locations":[{"facility":"Dept. of Neurology, University Hospital Muenster","city":"Muenster","state":"Nordrhein-Westfalen","zip":"48129","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}}]},"referencesModule":{"references":[{"pmid":"15236398","type":"BACKGROUND","citation":"Knecht S, Breitenstein C, Bushuven S, Wailke S, Kamping S, Floel A, Zwitserlood P, Ringelstein EB. Levodopa: faster and better word learning in normal humans. Ann Neurol. 2004 Jul;56(1):20-6. doi: 10.1002/ana.20125."},{"pmid":"15114342","type":"BACKGROUND","citation":"Breitenstein C, Wailke S, Bushuven S, Kamping S, Zwitserlood P, Ringelstein EB, Knecht S. D-amphetamine boosts language learning independent of its cardiovascular and motor arousing effects. Neuropsychopharmacology. 2004 Sep;29(9):1704-14. doi: 10.1038/sj.npp.1300464."},{"pmid":"16815467","type":"BACKGROUND","citation":"Breitenstein C, Floel A, Korsukewitz C, Wailke S, Bushuven S, Knecht S. A shift of paradigm: from noradrenergic to dopaminergic modulation of learning? J Neurol Sci. 2006 Oct 25;248(1-2):42-7. doi: 10.1016/j.jns.2006.05.012. Epub 2006 Jul 11."},{"pmid":"16273340","type":"BACKGROUND","citation":"Korsukewitz C, Breitenstein C, Schomacher M, Knecht S. [Present status and future possibilities of adjuvant pharmacotherapy for aphasia]. Nervenarzt. 2006 Apr;77(4):403-15. doi: 10.1007/s00115-005-2006-6. German."},{"pmid":"16880771","type":"RESULT","citation":"Breitenstein C, Korsukewitz C, Floel A, Kretzschmar T, Diederich K, Knecht S. Tonic dopaminergic stimulation impairs associative learning in healthy subjects. Neuropsychopharmacology. 2006 Nov;31(11):2552-64. doi: 10.1038/sj.npp.1301167. Epub 2006 Jul 26."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"meshes":[{"id":"D000007980","term":"Levodopa"},{"id":"D000077408","term":"Modafinil"},{"id":"D000068836","term":"Rivastigmine"}],"ancestors":[{"id":"D000000978","term":"Antiparkinson Agents"},{"id":"D000018726","term":"Anti-Dyskinesia Agents"},{"id":"D000015259","term":"Dopamine Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000697","term":"Central Nervous System Stimulants"},{"id":"D000064690","term":"Wakefulness-Promoting Agents"},{"id":"D000065701","term":"Cytochrome P-450 CYP3A Inducers"},{"id":"D000065693","term":"Cytochrome P-450 Enzyme Inducers"},{"id":"D000002800","term":"Cholinesterase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"}],"browseLeaves":[{"id":"M10672","name":"Levodopa","asFound":"Three months","relevance":"HIGH"},{"id":"M1789","name":"Modafinil","asFound":"Substance use","relevance":"HIGH"},{"id":"M317","name":"Rivastigmine","asFound":"Nasopharyngeal Carcinoma","relevance":"HIGH"},{"id":"M3985","name":"Antiparkinson Agents","relevance":"LOW"},{"id":"M7163","name":"Dopamine","relevance":"LOW"},{"id":"M17652","name":"Dopamine Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M3719","name":"Central Nervous System Stimulants","relevance":"LOW"},{"id":"M5730","name":"Cholinesterase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnDyAg","name":"Anti-Dyskinesia Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"CNSSti","name":"Central Nervous System Stimulants"},{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"CaAg","name":"Cardiotonic Agents"}]}},"hasResults":false}